Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration.
Glioblastoma multiforme (GBM), the most common malignant primary brain tumor, represents a significant disease burden. GBM tumor cells disperse extensively throughout the brain parenchyma, and the need for tumor-specific drug targets and pharmacologic agents to inhibit cell migration and dispersal is great. The receptor protein tyrosine phosphatase mu (PTPmu) is a homophilic cell adhesion molecule. The full-length form of PTPmu is down-regulated in human glioblastoma. In this article, overexpression of full-length PTPmu is shown to suppress migration and survival of glioblastoma cells. Additionally, proteolytic cleavage is shown to be the mechanism of PTPmu down-regulation in glioblastoma cells. Proteolysis of PTPmu generates a series of proteolytic fragments, including a soluble catalytic intracellular domain fragment that translocates to the nucleus. Only proteolyzed PTPmu fragments are detected in human glioblastomas. Short hairpin RNA-mediated down-regulation of PTPmu fragments decreases glioblastoma cell migration and survival. A peptide inhibitor of PTPmu function blocks fragment-induced glioblastoma cell migration, which may prove to be of therapeutic value in GBM treatment. These data suggest that loss of cell surface PTPmu by proteolysis generates catalytically active PTPmu fragments that contribute to migration and survival of glioblastoma cells.
Burgoyne
Adam M
AM
Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-4960, USA.
Phillips-Mason
Polly J
PJ
Burden-Gulley
Susan M
SM
Robinson
Shenandoah
S
Sloan
Andrew E
AE
Miller
Robert H
RH
Brady-Kalnay
Susann M
SM
D000818:Animals; D002448:Cell Adhesion / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D002470:Cell Survival / Q000235:genetics; D016543:Central Nervous System Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000628:therapy; D015536:Down-Regulation; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D005909:Glioblastoma / Q000201:enzymology* / Q000473:pathology / Q000628:therapy; D006801:Humans; D006868:Hydrolysis; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D054623:Receptor-Like Protein Tyrosine Phosphatases, Class 2 / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism*
D004791:Enzyme Inhibitors; D010446:Peptide Fragments; D012333:RNA, Messenger; D054623:Receptor-Like Protein Tyrosine Phosphatases, Class 2
J Cell Biol. 1995 Aug;130(4):977-86
7642713
Mol Cell Biochem. 1993 Nov;127-128:131-41
7935345
J Biol Chem. 2006 Jun 16;281(24):16189-92
16497667
Ann N Y Acad Sci. 2008 Oct;1142:108-32
18990124
J Biol Chem. 2000 Apr 14;275(15):11264-9
10753936
N Engl J Med. 2008 Jul 31;359(5):492-507
18669428
J Cell Sci. 2004 Jun 1;117(Pt 13):2675-86
15138284
J Biol Chem. 1994 Nov 11;269(45):28472-7
7961788
J Biol Chem. 1993 Aug 5;268(22):16101-4
8393854
Biochem J. 2007 Feb 15;402(1):1-15
17238862
J Biol Chem. 2007 Mar 23;282(12):9063-72
17259169
Am J Pathol. 2005 Apr;166(4):1247-58
15793303
Nat Rev Cancer. 2006 Apr;6(4):307-20
16557282
J Biol Chem. 2008 May 9;283(19):12691-700
18356166
Dev Biol. 2004 Nov 1;275(1):12-22
15464569
Neurosci Lett. 2006 Jul 24;402(3):278-83
16687212
Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46
17057753
J Biol Chem. 2000 Oct 6;275(40):31145-54
10878006
Cell. 2004 Jun 11;117(6):699-711
15186772
FEBS Lett. 1991 Sep 23;290(1-2):123-30
1655529
J Biol Chem. 2008 Nov 7;283(45):30879-89
18713734
Neuro Oncol. 2009 Dec;11(6):767-78
19304959
Biochem Soc Trans. 2008 Apr;36(Pt 2):167-72
18363557
J Biol Chem. 2006 Jun 16;281(24):16482-92
16613844
J Cell Biol. 1995 Oct;131(1):251-60
7559782
J Cell Biol. 1998 Apr 6;141(1):287-96
9531566
Int J Oncol. 1998 Nov;13(5):1077-80
9772302
Biochemistry. 1996 Mar 26;35(12):3797-802
8620001
Curr Opin Genet Dev. 2007 Feb;17(1):52-9
17178457
Nat Rev Cancer. 2003 Jul;3(7):489-501
12835669
Am J Pathol. 2007 May;170(5):1445-53
17456751
Biochim Biophys Acta. 2007 Jan;1773(1):78-88
17030444
Mol Cell Neurosci. 2007 Mar;34(3):481-92
17276081
Genes Dev. 2007 Nov 1;21(21):2683-710
17974913
Nat Protoc. 2006;1(5):2315-9
17406473
J Biol Chem. 2009 Jan 23;284(4):1954-61
19008223
Cancer Res. 2005 Aug 1;65(15):6850-7
16061668
J Cell Biol. 1993 Aug;122(4):961-72
8394372
Mol Cancer Res. 2008 Jul;6(7):1106-13
18644975
Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1683-8
8643690
Mol Cell Biol. 1999 May;19(5):3614-23
10207085
Mol Cell Biol. 2006 May;26(10):3917-34
16648485
Annu Rev Pathol. 2006;1:97-117
18039109
Cell Mol Life Sci. 2007 Feb;64(4):458-78
17260089
EMBO J. 2003 Aug 15;22(16):4223-36
12912920
J Biol Chem. 2002 Mar 29;277(13):11165-73
11801604
Cancer Res. 2007 Mar 1;67(5):1879-82
17332312
J Cell Biochem. 2008 Nov 1;105(4):1059-72
18773424